Pradžia › Suppuracinė hidradenitas › Ilinoisas
Suppuracinė hidradenitas klinikiniai tyrimai Ilinoisas
6 tyrimai dėl Suppuracinė hidradenitas ieško dalyvių vietose Ilinoisas.
Miestai Ilinoisas
Oficialus tyrimo tekstas (anglų kalba)
An Extension Study to Assess Safety and Efficacy of Remibrutinib in Participants With Moderate to Severe HS
- Endeavor Health, Glenview
- Dundee Dermatology, West Dundee
Renkami dalyviai3 fazė
Amžius nuo 18 iki 100 · Visoms lytims · Atnaujinta 2026-09-28 · NCT07665437ORKA-002 Versus Placebo in Participants With Moderate-to-Severe Hidradenitis Suppurativa
- Oruka Therapeutics Investigative Site, Chicago
Renkami dalyviai2 fazė
Amžius nuo 18 iki 79 · Visoms lytims · Atnaujinta 2026-09-24 · NCT07783542A Study to Investigate Efficacy and Safety With SAR445399 in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
- NorthShore University Health System - Endeavor Health Medical Group - Skokie - Woods Drive- Site Number : 8400019, Skokie
Renkami dalyviai2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-22 · NCT07225569Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib
- Investigative Site US125, Chicago
- Investigative Site US093, Chicago
- Investigative Site US039, West Dundee
Renkami dalyviai3 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-15 · NCT06855498Pharmacokinetics, Safety, and Efficacy of Povorcitinib in Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa
- Endeavor Health Medical Group, Skokie
Renkami dalyviai2 fazė
Amžius nuo 12 iki 17 · Visoms lytims · Atnaujinta 2026-08-06 · NCT07213973A Long-Term Follow-Up Observational Study to Evaluate Safety in Subjects Who Have Received a Gene-Modified Regulatory T Cell (Treg) Therapeutic
- Northwestern University, Chicago
Renkami dalyviaiStebimasis tyrimas
Amžius nuo 18 iki 71 · Visoms lytims · Atnaujinta 2026-04-16 · NCT07123038Iš ClinicalTrials.gov, duomenys gauti 2026-10-05. Kiekvienas tyrimas nustato savo tinkamumo kriterijus; tyrimo komanda sprendžia, kas gali dalyvauti.